Optimizing patient selection for prostate monotherapy.

  title={Optimizing patient selection for prostate monotherapy.},
  author={Adrian K. C. Lee and Delray J. Schultz and Andrew A Renshaw and Jerome P. Richie and Anthony V. D'Amico},
  journal={International journal of radiation oncology, biology, physics},
  volume={49 3},
PURPOSE Patients at low risk for prostate-specific antigen (PSA) failure following definitive local therapy are those with PSA of 10 or less, biopsy Gleason Score of 6 or less, and 1992 American Joint Committee on Cancer (AJCC) clinical Stage T1c or T2a. However, low-risk patients managed with radical prostatectomy and found to have prostatectomy Gleason… CONTINUE READING